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The recent use of Bacillus anthracis as a bioweapon has stimulated the search for novel antitoxins and vaccines that act
rapidly and with minimal adverse effects. B. anthracis produces an AB-type toxin composed of the receptor-binding
moiety protective antigen (PA) and the enzymatic moieties edema factor and lethal factor. PA is a key target for both
antitoxin and vaccine development. We used the icosahedral insect virus Flock House virus as a platform to display 180
copies of the high affinity, PA-binding von Willebrand A domain of the ANTXR2 cellular receptor. The chimeric virus-
like particles (VLPs) correctly displayed the receptor von Willebrand A domain on their surface and inhibited lethal
toxin action in in vitro and in vivo models of anthrax intoxication. Moreover, VLPs complexed with PA elicited a potent
toxin-neutralizing antibody response that protected rats from anthrax lethal toxin challenge after a single
immunization without adjuvant. This recombinant VLP platform represents a novel and highly effective, dually-acting
reagent for treatment and protection against anthrax.
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Introduction
Anthrax is caused by the spore-forming, Gram-positive
bacterium Bacillus anthracis [1]. The disease is elicited when
spores are inhaled, ingested, or transmitted through open
wounds in the skin. Inhalational anthrax is the deadliest form
of the disease, primarily because it is difﬁcult to diagnose in a
timely manner. Disease symptoms are initially nonspeciﬁc
and systemic dissemination of anthrax toxin can occur prior
to antibiotic treatment [2]. The deliberate release of B.
anthracis spores in the US in 2001, with the ensuing human
fatalities and enormous cleanup costs, has underscored the
need for better detection, treatment, and prevention of
anthrax.
The toxic effects of anthrax are predominantly due to an
AB-type toxin made up of a single receptor-binding B
subunit and two enzymatic A subunits [3]. The A subunits
are edema factor (EF, 89 kD), an adenylate cyclase that raises
intracellular cyclic adenosine monophosphate levels [4], and
lethal factor (LF, 90 kD), a zinc protease that cleaves mitogen-
activated protein kinase kinases [5,6]. The receptor-binding B
subunit is protective antigen (PA), which is initially synthe-
sized as an 83-kD precursor. Upon receptor binding, PA83 is
cleaved by furin into a 63-kD product that forms heptamers
that bind EF to form edema toxin (EdTx) and LF to form
lethal toxin (LeTx) [3]. Two anthrax toxin receptors, widely
distributed on human cells, have been identiﬁed: anthrax
toxin receptor/tumor endothelial marker 8 (ANTXR1) [7] and
capillary morphogenesis gene 2 (ANTXR2) [8]. Although both
receptors bind PA through a 200–amino acid extracellular
von Willebrand factor A (VWA) domain, the VWA domain of
ANTXR2 has a 1,000-fold higher binding afﬁnity for PA than
the VWA domain of ANTXR1. In addition, ANTXR2 has been
shown to mediate intoxication in vivo [11]. Recently, the low-
density lipoprotein receptor-related protein LRP6 was shown
to function as a co-receptor for anthrax toxin internalization,
although this ﬁnding is controversial [12,13].
The potential use of anthrax as a weapon of bioterrorism
has prompted increased efforts to develop better antitoxins
and vaccines. Protective immunity to B. anthracis infection is
conferred by antibodies against PA, which is the primary
component of anthrax-vaccine adsorbed (AVA; Biothrax), the
only currently licensed anthrax vaccine in the US. Although
AVA is safe and effective, it is molecularly ill-deﬁned, can
cause adverse reactions, and is administered in a lengthy
immunization schedule (six doses over 18 months) [14]. A
second-generation vaccine based on recombinant PA ad-
sorbed on aluminum hydroxide as adjuvant is currently in
development. Preliminary data indicate that it is less potent
than AVA, and it is likely that several immunizations will be
required to confer protection in humans [15]. Thus, the
development of a well-characterized vaccine that induces
rapid immunity after a single injection remains an important
goal.
To develop a reagent that functions both as an anthrax
antitoxin and as a molecular scaffold for an efﬁcient anthrax
Editor: Scott J. Hultgren, Washington University School of Medicine, United States
of America
Received January 23, 2007; Accepted August 13, 2007; Published October 5, 2007
Copyright:  2007 Manayani et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: AVA, anthrax-vaccine adsorbed; EF, edema factor; FHV, Flock
House virus; LeTx, lethal toxin; LF, lethal factor; MLD, minimum lethal dose; PA,
protective antigen; VLP, virus-like particle; VWA, von Willebrand A; wt, wild-type
* To whom correspondence should be addressed. E-mail: aschneem@scripps.edu
PLoS Pathogens | www.plospathogens.org October 2007 | Volume 3 | Issue 10 | e142 1422vaccine, we took advantage of an icosahedral virus platform
that permits polyvalent display of the extracellular VWA
domain of ANTXR2. This platform is based on Flock House
virus (FHV), a non-enveloped, icosahedral (T¼3) insect virus
of the family Nodaviridae [16]. The FHV capsid is composed
of 180 subunits of a single type of coat protein, and the
icosahedral solid shell encapsidates a bipartite, single-
stranded RNA genome. The crystal structure of FHV particles
shows that the coat protein contains several surface-exposed
loops that can be targeted for insertion of foreign proteins
and peptides [17]. Here, we report the synthesis and
structural characterization of FHV-VWAANTXR2 chimeric
particles and provide evidence for their efﬁcacy as an
anthrax toxin inhibitor in vitro and in vivo. In addition, we
used the chimeric particles as a scaffold for the multivalent
display of PA and show that this complex functions as a
potent vaccine against LeTx.
Results
FHV-VWAANTXR2 Chimeric Proteins Assemble into Virus-
Like-Particles
The VWA domain of ANTXR2 forms a compact structure
that adopts a Rossmann-like a/b-fold with a metal ion-
dependent adhesion site motif that is involved in PA binding
[9,18]. The N and C termini of this domain, residues C39 and
C218, respectively, are closely juxtaposed, thereby permitting,
in principle, genetic insertion into a loop on a carrier
protein. Modeling studies of the FHV coat protein subunit
indicated that two surface-exposed loops at amino acid
positions 206 and 264 would accommodate the 181 amino
acid ANTXR2 VWA domain without disrupting coat protein
assembly into virus-like particles (VLPs) (Figure 1A). Based on
these predictions, two chimeric proteins were generated. In
FHV-VWAANTXR2 chimera 206, the VWA domain and a C-
terminal two–amino acid linker (Ala-Glu) replaced FHV coat
protein residues 207–208 (Figure 1B). In FHV-VWAANTXR2
chimera 264, the VWA domain replaced FHV residues 265–
267. The chimeric proteins were expressed in Sf21 insect cells
using recombinant baculovirus vectors. In this system, wild-
type (wt) FHV coat protein forms VLPs whose high resolution
structure is virtually indistinguishable from that of native
virions (unpublished data). However, VLPs contain random
cellular RNA instead of the FHV genome and are therefore
not infectious [19].
Putative chimeric VLPs were puriﬁed from the cells by
sucrose gradient centrifugation and material sedimenting at a
position similar to that observed for native virions harvested
and analyzed by SDS-PAGE. As shown in Figure 1C, both
samples contained a major protein and a slower migrating
minor protein of the appropriate molecular weights (’63 kD,
the combined molecular weight of the 43-kD FHV coat
protein and the 20-kD ANTXR2 VWA domain). Since the
FHV coat protein undergoes a spontaneous cleavage reaction
after assembly of particles (Figure 1B) [20], the minor protein
likely represented the unprocessed precursor protein, where-
as the major protein represented the post-assembly cleavage
product. Capsid proteins representing chimera 264 migrated
more slowly through the gel than those representing chimera
206, even though the amino acid composition of the two
polypeptides was virtually identical. The reason for this
differential behavior is not known but could reﬂect subtle
differences in denaturation of the proteins under SDS-PAGE
conditions.
Electron microscopy of negatively stained samples con-
ﬁrmed the presence of VLPs in the gradient-puriﬁed material
(Figure 1D). Compared to the smooth exterior of native FHV
virions, the surface of the chimeric particles was rough and
distinct protrusions were visible. The appearance of the
particles suggested that they were ﬁlled with RNA, as stain did
not penetrate the interior. This conclusion was supported by
the sedimentation rate of the VLPs, which was indistinguish-
able from that of wt FHV (not shown).
FHV-VWAANTXR2 VLPs Protect Cultured Cells from
Intoxication
The soluble, monomeric ANTXR2 VWA domain
(sANTXR2), expressed and puriﬁed from mammalian cells,
was previously shown to effectively block entry of LeTx into
susceptible cells by competing with cellular ANTXR2 for
binding to PA [10]. PA has a very high binding afﬁnity for
sANTXR2 (Kd ¼ 170 pM) and dissociates extremely slowly
from this receptor decoy (the half-life of the complex is
approximately 17 h) [21]. We used the same approach to test
the inhibitory activity of FHV-VWAANTXR2 VLPs. Namely, the
assay employed CHO-K1 cells and a modiﬁed form of LeTx,
PA/LFN-DTA, in which the N-terminal portion of LF was
fused to the catalytic portion of diphtheria toxin A-chain
[22]. This recombinant toxin efﬁciently kills CHO-K1 cells
within 48 h and uses the same PA-dependent entry
mechanism as wt LF. The assay revealed that chimera 264
protected cells as efﬁciently as sANTXR2, whereas a higher
concentration of chimera 206 was required to achieve
protection of the cells (Figure 2). The corresponding IC50
values for sANTXR2 and chimera 264 were 19.70 6 0.87 nM
and 18.50 6 0.36 nM, respectively, while the IC50 was 32.71 6
0.61 nM for chimera 206. Thus, chimera 264 performed as
well as the highly potent, monomeric sANTXR2 inhibitor in
this assay. To conﬁrm the ability of the particles to neutralize
native LeTx, a macrophage-based toxin neutralization assay
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Author Summary
Anthrax is caused by the spore-forming, Gram-positive bacterium
Bacillus anthracis. The toxic effects of B. anthracis are predominantly
due to an AB-type toxin made up of the receptor-binding subunit
protective antigen (PA) and two enzymatic subunits called lethal
factor and edema factor. Protective immunity to B. anthracis
infection is conferred by antibodies against PA, which is the primary
component of the current anthrax vaccine. Although the vaccine is
safe and effective, it requires multiple injections followed by annual
boosters. The development of a well-characterized vaccine that
induces immunity after a single injection is an important goal. We
developed a reagent that combines the functions of an anthrax
antitoxin and vaccine in a single compound. It is based on
multivalent display of the anthrax toxin receptor, ANTXR2, on the
surface of an insect virus. We demonstrate that the recombinant
virus-like particles protect rats from anthrax intoxication and that
they induce a potent immune response against lethal toxin when
coated with PA. This immune response protected animals against
lethal toxin challenge after a single administration without adjuvant.
The PA-coated particles have significant advantages as an immu-
nogen compared to monomeric PA and form the basis for
development of an improved anthrax vaccine.was performed with chimera 264. The assay revealed that the
particles protected RAW264.7 cells efﬁciently from a mixture
of PA and wt LF, and the measured IC50 was 39.8 6 2.2 nM.
FHV-VWAANTXR2 Chimera 264 Protects Rats from LeTx
Challenge
We next tested whether the chimeric particles were capable
of protecting rats against LeTx challenge as was demon-
strated previously for sANTXR2 [10]. In vivo experiments
were only performed with chimera 264 because it had shown
higher potency in the cell intoxication assay (Figure 2). As a
positive control, sANTXR2 was used in parallel. Male Fisher
344 rats were inoculated intravenously with 5 minimal lethal
doses (MLDs) of LeTx either in the presence or absence of
chimera 264 or sANTXR2 as previously described [10]. As
shown in Table 1, both chimera 264 and sANTXR2
completely protected the animals when used at a molar ratio
of 2:1 (ANTXR2:PA). Moreover, the animals did not exhibit
any symptoms of intoxication such as agitation, respiratory
distress, or hypoxia. Injection vehicle (PBS) or wt FHV, used
as a negative control, had no protective effect. While neither
chimera 264 nor sANTXR2 were able to protect rats when
used at a 10-fold lower concentration (molar ratio of
ANTXR2:PA ¼ 0.2:1), they each caused a delay in the time
to death compared to the LeTx control (Table 1). The delay
was notably longer for chimera 264 (89 min) than sANTXR2
(77 min), and the difference was highly signiﬁcant (p¼0.0046),
suggesting increased therapeutic potency of the multivalent
particles over monomeric sANTXR2 as an inhibitor of the
anthrax toxin. It will be interesting to determine whether
different pharmacokinetic proﬁles are observed in vivo for
sANTXR2 and chimera 264.
Structural Analysis of FHV-VWAANTXR2 VLPs
Electron cryomicroscopy and image reconstruction of the
FHV-VWAANTXR2 VLPs showed that, compared to wt FHV
particles (Figure S1C), both chimeric particles displayed
additional density at higher radius (Figure S1A and S1B),
which is in agreement with the protrusions that were visible
in negatively stained samples (Figure 1D). To deﬁne the
arrangement of the VWA domains on the surface of the
chimeric particles, pseudoatomic models were generated by
ﬁtting the X-ray coordinates of the FHV coat protein subunit
and the ANTXR2 VWA domain into the cryoEM density maps
(Figures 3A, 3B, S2A, and S2B). The models revealed that in
chimera 206 the VWA domains were closely juxtaposed at the
quasi 3-fold axes. Two of the three VWA domains in each
asymmetric unit closely interacted with their 2-fold related
counterparts, thereby creating an offset cluster of six
domains. In contrast, the insertion site chosen for chimera
264 allowed for wider spacing and more even distribution of
the individual VWA domains on the particle surface.
To investigate the accessibility of PA to the VWA domains,
PA83 was computationally docked onto the VWA domains of
the pseudoatomic models of chimeras 264 and 206 using the
X-ray structure of PA complexed with the ANTXR2 VWA
domain as a guide [9,18]. It was evident that chimera 264
could accommodate signiﬁcantly more PA molecules than
chimera 206 given the wider spacing of the VWA domains on
this particle (Figures 3C, 3D, S3A, and S3B). Speciﬁcally, each
subunit at the 5-fold axes and three of the six subunits around
the quasi-6-fold axes could bind PA83 without steric
interference, giving a total occupancy of 120 PA molecules
per particle. In contrast, due to the close juxtaposition of the
VWA domains on chimera 206, a maximum occupancy of 60
PA molecules per particle was predicted. These predictions
Figure 1. Design and Analysis of FHV-VWAANTXR2 VLPs
(A) Ribbon diagram of a single FHV coat protein subunit showing the surface-exposed loops into which the VWA domain of ANTXR2 was inserted.
(B) Schematic diagram showing structure of FHV-VWAANTXR2 chimeric proteins 206 (top) and 264 (bottom). Numbers refer to amino acid positions in the
FHV coat protein. The assembly-dependent autocatalytic maturation cleavage occurs between Asn 363 and Ala 364.
(C) Electrophoretic analysis of purified VLPs on a 10% Bis-Tris gel stained with Simply Blue (Invitrogen). Lane 1, molecular weight markers; lane 2, wt FHV
VLPs; lane 3, FHV-VWAANTXR2 chimera 206; lane 4, FHV-VWAANTXR2 chimera 264.
(D) Electron micrographs of gradient-purified wt and chimeric VLPs negatively stained with uranyl acetate. Bar ¼ 500 A ˚.
doi:10.1371/journal.ppat.0030142.g001
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analyses of complexes formed between the particles and
PA83 under saturating conditions. Speciﬁcally, gel electro-
phoresis combined with densitometric analysis showed that
chimera 206 could bind an average of 90 PA83 ligands,
whereas chimera 264 bound an average of 130 PA83 ligands
(Figures S4A and 4B). Together, these results were consistent
with the observation that a higher concentration of chimera
206 was required to protect cells from intoxication with PA/
LFN-DTA (Figure 2).
FHV-VWAANTXR2 Particles Serve as a Highly Effective
Vaccine Platform
The observation that FHV-VWAANTXR2 chimera 264
functioned as a binding surface for multiple copies of PA
suggested that a complex of the two components might
constitute an effective antigen for induction of PA-speciﬁc
antibodies. To test this, complexes were prepared by mixing
chimera 264 with an excess of PA83, and unbound PA83 was
removed by ultracentrifugation. Electron microscopic anal-
ysis showed that PA83 formed thin protrusions emanating
from the capsid surface (not shown).
For immunogenicity studies, rats (four per group) received
two subcutaneous injections (0 and 3 wk) of either 2.5 lgo f
PA83, 5.4 lg of particle–PA complex (molar equivalent of 2.5
lgo fP A 83 assuming an occupancy of 120 VWA domains), or
2.9 lg of chimera 264. No adjuvants were employed in these
experiments. The ELISA assay of pre- and post-inoculation
sera showed that animals immunized with the complex had
signiﬁcantly higher levels of anti-PA antibody than animals
receiving PA alone both at week 3 (p¼0.0028 compared to PA
alone) and after boosting (week 7; p¼0.0118 compared to PA
alone) (Figure 4A). No signiﬁcant antibody response against
ANTXR2 VWA was detected in these animals, but a response
against FHV protein was observed after the boost in rats that
were immunized with the complex (Figure 4B and 4C). Why
animals immunized with chimera 264 alone did not mount a
similar immune response against FHV protein is not clear.
The presence of PA may somehow enhance the response to
FHV or may inﬂuence the localization or interaction of FHV
particles with antigen-presenting cells, causing a difference in
the observed anti-FHV antibody response.
To test whether the anti-PA antibodies were protective
against anthrax toxin, the rats were challenged by intra-
venous inoculation with 10 MLDs of LeTx. All animals that
had been immunized with the particle–PA complex survived,
whereas all but one of the animals in the PA83 group died
(Figure 4D). Survival versus death correlated well with the
level of anti-PA antibody detected in the sera. However, the
animal in the PA-only group that survived LeTx challenge
had a serologic response to PA that was well below that of a
non-surviving animal in the same group (Figure 4D).
Based on the observation that animals immunized with the
particle–PA complex showed a signiﬁcant level of anti-PA
antibody as early as 3 wk after the ﬁrst immunization (Figure
4A), we investigated whether animals could be protected
against LeTx after a single injection. Rats (ﬁve per group)
were immunized once with increased doses of the particle–PA
complex (10.8 lg), PA83 (5 lg), or chimera 264 (5.8 lg) as a
control. After 3 wk, the animals were bled and challenged 1
wk later with 10 MLDs of LeTx. All rats that were immunized
with the particle–PA complex survived, whereas all other
animals died (Figure 4F). Of those that died, one animal had a
serologic antibody response to PA that was greater than that
of two animals in the group of survivors (Figure 4E and 4F),
indicating that the magnitude of the antibody response is not
a reliable predictor of protection. Taken together, our results
show that multivalent display of PA on the FHV-VWAANTXR2
scaffold yields a signiﬁcant advantage over monovalent,
soluble PA as an immunogen for anthrax toxin.
Discussion
In this study we have developed a novel reagent that
combines the functions of anthrax antitoxin and vaccine in a
single compound. It is based on multivalent display of the
Table 1. In Vivo Intoxication Experiments in Fisher 344 Rats
Groups Molar Ratio of
VWAANTXR2 :P A
Survivors/
Total
Average TTD
6 SD (min)
PBS NA 3/3 NA
LeTx NA 0/5 69.2 6 1.5
FHV wt þ LeTx NA 0/3 67.7 6 5.1
sANTXR2 þ LeTx 2:1 5/5 NA
sANTXR2 þ LeTx 0.2:1 0/5 77 6 4.6
FHV-VWAANTXR2 264 þLeTx 2:1 5/5 NA
FHV-VWAANTXR2 264þ LeTx 0.2:1 0/5 89.4 6 5.4
PBS vehicle of injection as negative control, LeTx (20 lg [240 pmol]) of PA, and 8 lg (89
pmol) of LF, FHV wt was injected at a concentration of 21 lg/rat (480 pmol).
NA, not applicable; TTD, time to death.
doi:10.1371/journal.ppat.0030142.t001
Figure 2. Dose Response Curve Showing Cell Viability as a Function of
Antitoxin Concentration
CHO-K1 cells were incubated with PA-LFNDTA in the presence of
increasing concentrations of sANTXR2, chimera 206, or chimera 264.
After incubation at 37 8C for 48 h, cell viability was determined with
Celltiter-glo (Promega). Data points represent the mean 6 SD values for
triplicate samples. All data were normalized to untreated cell controls.
doi:10.1371/journal.ppat.0030142.g002
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FHV-Based Anthrax Antitoxin and VaccineANTXR2 VWA domain on the surface of the icosahedral
insect nodavirus FHV. We demonstrate that the recombinant
VLPs protect cultured cells and rats from anthrax intoxica-
tion as efﬁciently as the highly potent sANTXR2 receptor
decoy and that they induce a potent immune response against
LeTx when coated with PA. This immune response was
neutralizing in vitro and protected animals against LeTx
challenge following a single administration without adjuvant.
The motivation for immunogenicity studies was based on
the assumption that polyvalent display of PA would induce a
more potent immune response than monomeric, recombi-
nant PA, which is currently being developed as a second-
generation anthrax vaccine [15,23]. Ordered arrays of
antigens are known to permit particularly efﬁcient cross-
linking of B cell receptors, which in turn leads to faster and
more robust B cell proliferation [24–26]. Given the excep-
tionally tight binding of PA to ANTXR2 under natural
conditions (Kd ¼ 170 pM) [21], we reasoned that complexes
formed between chimera 264 and PA would be sufﬁciently
stable to serve as an immunogen in vivo. In support of this
notion, results from in vitro cell intoxication experiments
indicated that the complexes were stable for at least 40 h at 37
8C. Based upon a recent observation that naturally occurring
PA neutralizing antibodies do not bind to the receptor-
binding surface of PA [27], we reasoned that PA immobilized
on these particles should be able to elicit a protective
immune response. Indeed, rats survived LeTx challenge 4 wk
after a single injection of the VLP-PA complex, whereas
animals injected with an equivalent amount of recombinant
PA died. This result suggested rapid production of neutraliz-
ing antibodies in the absence of adjuvant, two key goals for
the development of third-generation anthrax vaccines. No
signiﬁcant antibody response to ANTXR2 was observed,
presumably because there are only two–amino acid differ-
ences between human ANTXR2 displayed on the particle and
endogenous rat ANTXR2 [11].
An essential next step will be to characterize the neutraliz-
ing antibody response in individual animals after primary
and secondary immunization. An important component of
this analysis will be to determine the mechanism by which
toxin neutralization occurs. For example, we noticed a slight
difference in antibody response after primary and secondary
immunization and a wide range of antibody titers between
individual animals (Figure 4). It will be of key interest to
establish whether these differences correlate with epitope
speciﬁcity or are based on other immunologic parameters. In
addition, it will be critical to conﬁrm our ﬁndings in a B.
anthracis spore challenge model, and studies to this end are
currently underway.
Because the chimeric particles are expressed from an
mRNA that contains only the coding sequence of the
modiﬁed FHV coat protein while all other FHV sequences
are missing, the resulting VLPs are not infectious and thus
cannot replicate in mammalian tissues [19]. Even native FHV
particles are unable to initiate infection in mammals, as they
do not carry the FHV receptor, and because FHV cannot
replicate at temperatures above 31 8C [28]. We have also
demonstrated previously that FHV VLPs expressed from
baculovirus vectors in Sf21 cells do not contain baculoviral or
cellular DNA [19], thus ruling out potential integration of
foreign DNA into mammalian genomes. Based on these
properties, the chimeric particles can be expected to have a
desirable safety proﬁle for applications in animals and
humans.
The idea of combining the functions of anthrax vaccine
and antitoxin in a single reagent has been explored
previously. Aulinger et al. [29] demonstrated that a domi-
nant-negative, inhibitory form of PA, DNI-PA, can elicit an
antibody response that protects mice from LeTx challenge.
DNI-PA forms mixed heptamers with wt PA and thereby acts
as an antitoxin to block toxin translocation both in vitro and
in vivo [30]. However, even after two injections in the
presence of adjuvant there was only a weak antibody response
to DNI-PA, and a third injection had to be performed to
generate a sufﬁcient antibody response to protect against
LeTx challenge [29].
While the potency of the nanoparticles as a vaccine is most
likely due to polyvalent display of PA, polyvalency is less of a
factor in the function of the particles as an antitoxin given
the extremely high afﬁnity between PA and ANTXR2.
Moreover, since PA binds as a monomer to the particles,
little, if any, polyvalent effect is to be expected. In fact, we
detected no signiﬁcant difference in IC50 when comparing
nanoparticles with soluble ANTXR2 in cell intoxication
assays. That polyvalency increases the afﬁnity between a
ligand and its target receptor is a well-established phenom-
enon [31]. Recently, Rai et al. [32] reported that ‘‘pattern
Figure 3. Three-Dimensional Models of FHV-VWAANTXR2 VLPs with and
without Bound PA83
(A, B) Pseudoatomic models of FHV-VWAANTXR2 chimeras. X-ray
coordinates of FHV capsid protein (green) and ANTXR2 VWA domain
(yellow) were docked into the cryoEM density of chimera 206 (A) and
chimera 264 (B). Panels show surface views of the particles in the
absence of the cryoEM density maps. Note the different distributions of
the ANTXR2 domains on the surfaces of the VLPs.
(C, D) In silico model of PA83 bound to the surface of FHV-VWAANTXR2
chimeras. PA83 (purple) was modeled onto the surface of chimera 206 (C)
and chimera 264 (D) using the known high resolution X-ray structure of
the ANTXR2-VWA/PA63 complex as a guide [9]. Panels show surface
views of the entire particles to illustrate the difference in occupancy of
PA83 on the two chimeras.
doi:10.1371/journal.ppat.0030142.g003
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reach its maximum potential. With this approach, they
achieved similar IC50 values in cell intoxication assays for
liposomes containing inhibitory peptides that block LF
binding to the PA heptamer as we observed for our
nanoparticles. However, the functionalized liposomes de-
scribed in their study are without a vaccine application.
In vivo potency of viral nanoparticles is also signiﬁcantly
determined by their pharmacokinetic parameters. Such
parameters have recently been reported for viral nano-
particles derived from the plant virus cowpea mosaic virus
[33]. It will be important to determine whether there are
signiﬁcant differences in the plasma clearance kinetics and
biodistribution of soluble ANTXR2 versus ANTXR2-contain-
ing nanoparticles.
The VWA domain of ANTXR2 was a particularly appealing
candidate for insertion into a loop of the FHV coat protein
because the N and C termini are only separated by 4.8 A ˚ in
the native structure [34]. In addition, this domain adopts a
compact Rossmann-like a/b-fold that can evidently form
independently within the context of a larger protein while
not interfering with accurate folding of the carrier protein.
This hypothesis was supported by the observation that the
high-resolution structure of the VWA domain could be ﬁtted
easily into the cryoEM density maps. To our knowledge,
hepatitis B virus is the only other virus for which icosahedral
surface display of an entire protein in its biologically active
conformation has been demonstrated. In that case, genetic
insertion of the green ﬂuorescent protein in a surface-
exposed loop of the core protein resulted in efﬁcient
formation of ﬂuorescent hepatitis B virus capsids [35].
In principle, it should be possible to expand the use of the
Figure 4. Antibody and LeTx Challenge Response of immunized Rats
(A–D) Rats (four per group) were immunized with FHV-VWAANTXR2–PA83 complex, FHV-VWAANTXR2 chimera alone, PA83, or PBS and boosted 4 wk later.
Serum samples were collected prior to as well as 3 and 7 wk after immunization and tested by ELISA for IgG-specific antibody response to (A) PA,
(B)VWAANTXR2, and (C) FHV coat protein. Data represent the mean 6 SD of animals in the respective groups and are shown for the 1:1,000 serum
dilution in panels (A) and (B) and for the 1:100 serum dilution in panel (C). In panel (A) at week 3, * indicates p¼0.003 compared to PBS control and **
indicates p ¼ 0.003 compared to PA83 alone. At week 7, * indicates p ¼ 0.005 compared to PBS control and ** indicates p ¼ 0.012 compared to PA83
alone. (D) Relationship between anti-PA antibody level and survival of individual rats following challenge with 10 MLDs of LeTx.
(E, F) Rats (five per group) were immunized once with FHV-VWAANTXR2–PA83 complex, FHV-VWAANTXR2 chimera alone, PA83, or PBS. Serum samples were
collected prior to and 3 wk after immunization, diluted 1:100, and tested for IgG-specific antibody response to PA (E). Data represent the mean 6 SD of
animals in the repective groups. At week 3, * indicates p , 0.0001 compared to PBS control and ** indicates p ¼ 0.001 compared to PA83 alone. (F)
Relationship between anti-PA antibody level and survival of individual rats following challenge with 10 MLDs of LeTx.
doi:10.1371/journal.ppat.0030142.g004
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the presence or absence of the ANTXR2 VWA domain.
Speciﬁcally, direct insertion of peptides or entire domains
derived from PA, LF, and EF may be feasible as long as the
termini of the domains are in close enough proximity for
insertion into the FHV coat protein loops. It is also
conceivable that the two insertion sites at positions 206 and
264 could be used in combination to create particles with
multiple functionalities. This could greatly enhance the
protection afforded by the resulting particles.
Numerous other strategies are being pursued to develop
improved anthrax vaccines, including PA-expressing Salmo-
nella [36] and B. subtilis [37], adenovirus encoding PA domain
4 [38], rabies virus encoding GP-PA fusion protein [39], and
bacteriophage T4 particles decorated with PA-hoc fusion
proteins [40–42]. None of these, however, combine the
function of vaccine and antitoxin. In those cases where
immunized animals were challenged with LeTx or anthrax
spores, only the adenovirus construct provided complete
protection after a single immunization [38]. The strategy
most comparable to that described in our study involves non-
covalent surface display of intact proteins and protein
complexes on bacteriophage T4 particles. The prolate lattice
of the T4 capsid permits efﬁcient surface presentation of
anthrax toxin through in vitro addition of Hoc- and/or Soc
protein fusions with PA, LF, or EF to hoc
 soc
  phage either
separately or in combination [40,42]. Mice immunized with
phage displaying PA, EF, and LF generated high levels of
neutralizing antibodies [41], but results from toxin or spore
challenge experiments have not yet been reported.
In summary, we have developed a reagent that serves a dual
purpose in combating B. anthracis infection. It functions as a
competitive inhibitor of anthrax toxin in vivo, suggesting that
it could be useful as a therapeutic compound, particularly in
combination with standard antibiotic therapy. In addition,
when complexed with PA, it has signiﬁcant advantages as an
immunogen compared to monomeric PA and thus forms the
basis for development of an improved anthrax vaccine.
Materials and Methods
Construction of recombinant baculoviruses. DNA fragments
encoding FHV coat protein-ANTXR2 VWA domain chimeras were
generated by overlap extension PCR using Pfu polymerase [43]. Three
DNA fragments containing the nucleotide sequence for the N-
terminal portion of the coat protein, the ANTXR2 VWA domain
(GenBank accession number AY23345, nts 115–657, amino acids 38–
218), and the C-terminal portion of the coat protein, were initially
generated. The template used for generating segments containing the
FHV coat protein sequence was plasmid pBacPAK9RNA2d [44],
which contains the full-length cDNA of FHV RNA2 in baculovirus
transfer vector pBacPAK9 (BD Biosciences). The template used for
generating the segment containing the ANTXR2 VWA coding
sequence was a derivative of plasmid PEGFP-N1 [8]. Following
overlap extension PCR, the full-length product was digested with
BamH1 and XbaI, gel-puriﬁed, and ligated into equally digested
pBacPAK9. The transfer vector was ampliﬁed in E. coli strain DH5a,
puriﬁed, and sequenced to conﬁrm the presence of the ANTXR2
VWA sequence and to ensure the absence of inadvertent mutations.
Recombinant baculoviruses AcFHV-VWAANTXR2-264 and AcFHV-
VWAANTXR2-206 were generated by transfecting Sf21 cells with a
mixture of transfer vector and linearized Bsu36I-linearized BacPAK6
(BD Biosciences) baculovirus DNA as described previously [43].
Cells and infection. Spodoptera frugiperda cells (line IPLB-Sf21) were
propagated and infected as described previously [19]. Trichoplusia ni
cells were propagated and infected as described by Dong et al. [45]
except that EX-CELL 401 medium was replaced with ESF921
(Expression Systems).
Puriﬁcation of virus-like particles (VLPs). VLPs were puriﬁed from
T.ni suspension cultures 5 to 6 days after infection. NP-40 substitute
(Fluka) was added to the culture to a ﬁnal concentration of 1% (v/v)
followed by incubation on ice for 10–15 min. Cell debris was pelleted
by centrifugation in a Beckman JA-14 rotor at 15,300g for 10 min at 4
8C. VLPs in the supernatant were precipitated by addition of NaCl to
a ﬁnal concentration of 0.2 M and polyethylene glycol 8000 (Fluka) to
a ﬁnal concentration of 8% (w/v) and stirring the mixture at 4 8C for 1
h. The precipitate was collected by centrifugation at 9,632g for 10
min at 4 8C in a JA-14 rotor and resuspended in 50 mM Hepes buffer
(pH 7.5). Insoluble material was removed by centrifugation at 15,300g
for 20 min at 4 8C. VLPs in the clariﬁed supernatant were pelleted
through a 4-ml 30% (w/w) sucrose cushion in 50 mM Hepes (pH 7.5)
by centrifugation in a Beckman 50.2 Ti rotor at 184,048g for 2.5 h at
11 8C. The pellet was resuspended in 50 mM Hepes buffer (pH 7.5)
and loaded onto a 10%–40% (w/w) sucrose gradient in the same
buffer. The gradients were spun in a Beckman SW 28 rotor for 3 h at
103,745g. VLPs were collected from the gradient by inserting a needle
below the VLP band and aspirating the material into a syringe.
Alternatively, gradients were fractionated with continuous absorb-
ance at 254 nm on an ISCO gradient fractionator at 0.75 ml/min and
0.5 min per fraction. Fractions containing VLPs were then dialyzed
against 50 mM Hepes, (pH 7.5) and concentrated to 1–5 mg/ml using a
centrifugal concentrator with a 100,000 MW cut off (Amicon,
Millipore). The ﬁnal protein concentration was determined by BCA
assay (Pierce Chemicals) and purity was evaluated by densitometry
(FluorChem SP, Alpha Innotech) after electrophoresis on a 10% Bis-
Tris gel stained with Simply Blue (Invitrogen).
Electron microscopy. Samples of gradient-puriﬁed VLPs were
negatively stained with 1% (w/v) uranyl acetate. A drop of each
sample was adsorbed to a glow-discharged, collodion-covered copper
grid and allowed to adsorb for 1–2 min. Excess solution was removed
by blotting with ﬁlter paper. The grids were washed and blotted with
ﬁlter paper three times by ﬂoating on droplets of 50 mM Hepes (pH
7.5). Each grid was then treated three times with a drop of 1% uranyl
acetate solution and left in the third drop for 1–2 min prior to
blotting and air drying. The samples were viewed in a Philips/FEI CM
100 transmission electron microscope at 100 kV.
Electron cryomicroscopy and image reconstruction. Frozen-hy-
drated samples were prepared using standard methods [46]. In brief,
an aliquot of the sample was applied to a glow-discharged Quantifoil
holey carbon-coated grid (2/4 Cu-Rh), blotted with ﬁlter paper, and
rapidly plunged into liquid ethane. Low-dose electron micrographs
of FHV-VWAANTXR2-264 VLPs were recorded onto Kodak SO163
ﬁlm at a magniﬁcation of 45,0003 on a Philips/FEI CM120 trans-
mission electron microscope. For FHV-VWAANTXR2-206 VLPs, low-
dose micrographs were recorded on a CCD camera at a magniﬁca-
tion of 50,0003 on a Philips/FEI Tecnai20 transmission electron
microscope. The grids were maintained at 180 8C using a Gatan 626
cryo-stage. Micrographs with minimal astigmatism and drift, as
assessed by visual inspection and optical diffraction, were digitized
with a Zeiss microdensitometer (Z/I Imaging), giving a step-size of 3.1
A ˚ on the specimen. Images recorded on the CCD camera had a step-
size of 2.26 A ˚ . Particle images were extracted with the program X3D
[47] and were processed by polar Fourier transform methods using
the program PFT [48]. A previously calculated model of wt FHV [49]
was used as the starting model. Initial reﬁnement cycles were
restricted to the radii spanning the FHV capsid and then relaxed to
incorporate the extra domains. Using a Fourier shell correlation cut-
off value of 0.5, the FHV-VWAANTXR2-206 and FHV-VWAANTXR2-264
maps were reﬁned to resolutions of 25 and 23 A ˚ , respectively.
Generation of pseudoatomic models. The atomic coordinates of
the FHV coat protein subunit and the VWA domain of ANTXR2
(PDB ID: 1SHT) were used to generate a pseudoatomic model of the
FHV-VWAANTXR2-206/264 VLPs. Speciﬁcally, the models were cre-
ated with the program O [50] by visually positioning the ANTXR2
VWA domains at the surface of the FHV structure and adjusting for
overlap. The models were then further reﬁned against the structure
factor amplitudes derived from the cryoEM density using the
program CNS [51]. Individual subunits and domains of the FHV-
VWAANTXR2 chimera were allowed to move independently as rigid
bodies and subjected to ﬁve rounds of 20 cycles of rigid body
reﬁnement. PA83 molecules were docked onto the resulting FHV-
VWAANTXR2-206/264 models using the structure of PA63 complexed
with the ANTXR2 VWA domain (PDB ID: 1T6B) as a guide [9]. Once
all 180 ANTXR2 VWA domains on the FHV-VWAANTXR2 chimera
were populated with PA83 molecules, a minimal number of PA
molecules were selectively removed to relieve steric clashes with
neighboring PA molecules.
Quantiﬁcation of PA83 bound to chimeras 206 and 264. Recombi-
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(pH 7.5) was mixed with puriﬁed chimeras 206 and 264 in 50 mM
Hepes (pH 7.5) in a ratio of 180:1 (equimolar amounts of PA83 and
VWA domains). Following incubation for 20 min at room temprature,
an aliquot from each of the samples was removed and stored at 20 8C
pending analysis. The remainder of the samples was transferred to an
ultracentrifuge tube and underlayed with a 30% (w/w) sucrose
cushion in 50 mM Hepes (pH 7.5). Complexes of chimeras decorated
with PA83 were pelleted by centrifugation at ;200,000g for 45 min.
The complexes were resuspended in 50 mM Hepes, mixed with SDS
loading buffer, and heated at 95 8C for 10 min. Aliquots were
electrophoresed through a 4%–12% Bis-Tris polyacrylamide gel, in
parallel with the aliquots taken before pelleting. The gels were
stained with Simply Blue (Invitrogen). The amount of protein in each
band was determined by densitometric analysis using FluorChem SP
(Alpha Innotech).
Cell intoxication assay with CHO-K1 cells. Cell intoxication studies
were performed in CHO-K1 cells as described previously [10]. Brieﬂy,
5 3 10
3 cells in 100 ll of Hams-F12 nutrient mixture (Gibco BRL)
supplemented with 10% fetal bovine serum were plated into wells of
a 96-well microtitre plate a day prior to the assay. Varying amounts of
FHV-VWAANTXR2 VLP or soluble ANTXR2 [8] were preincubated for
20 min in 100 ll of medium containing PA and LFN-DTA at a molar
concentration of 10
 8 and 10
 10, respectively. The mixture was added
to the cells, which were incubated at 37 8C for approximately 40 h.
The medium was then replaced with 50 ll of Celltiter-glo reagent
(Promega) diluted 1:1 with PBS. Luciferase activity as a measure of
cell viability was determined with a luminometer (TopCount NXT,
Perkin Elmer). Non-linear regression analysis was used to calculate
IC50 values (Prism, GraphPad Software).
Marophage-based toxin neutralization assay. RAW264.7 cells (5 3
10
4) were plated in each well of a white 96-well tissue culture plate
(Corning Costar) with 100 ll of Dulbecco’s Modiﬁed Eagle Medium
(Gibco) supplemented with 10% standard fetal bovine serum the day
before the assay. Varying amounts of FHV-VWAANTXR2 VLP were
preincubated for 20 min in 400 ll of medium containing PA and LF
at a molar concentration of 10 8 and 10
 9, respectively. The mixture
(100 ll) was added to the cells in triplicate and incubated at 37 8C for
approximately 5 h. Cell viability was determined as described for
CHO-K1 cells.
LeTx challenge with FHV-VWAANTRX2 VLPs. LeTx challenge
experiments were performed in cannulated, male Fisher 344 rats
(180–200 g, Harlan) according to protocols approved by the Scripps
Institutional Animal Care and Use Committee. LeTx for each rat was
prepared by mixing 20 lg of PA and 8 lg of LF (List Biological
Laboratories). All rats were anesthetized with isoﬂuorane and
inoculated through a jugular vein cannula with 500 ll of LeTx
(control), or LeTx premixed with FHV-VWAANTXR2 VLPs or
sANTXR2 (test). Additional rat control groups were injected with
either PBS or wt FHV. Rats recovered from anesthesia within 5 min
after dosing and were monitored for symptoms of intoxication
(agitation, respiratory distress, hypoxia) and death as determined by
cessation of respiration.
Statistical analysis. Data are presented as mean 6 SD. Signiﬁcance
was reported using the Student’s unpaired T-test (Prism, GraphPad
Software). p-Values ,0.05 were considered statistically signiﬁcant.
Data were also analyzed using 2-way ANOVA followed by Tukey’s
post-comparison test to conﬁrm signiﬁcance.
Preparation of FHV-VWAANTRX2 chimera 264-PA83 complexes.
Puriﬁed chimera 264 VLPs in 50 mM Hepes (pH 7.5) were mixed with
a 4-fold molar excess of recombinant PA83 (List Biological Labo-
ratories) in 5 mM Hepes, 50 mM NaCl (pH 7.5), and incubated at
room temperature for 20 min with mild agitation. The sample was
then transferred to an ultracentrifuge tube and underlayed with a
30% (w/w) sucrose cushion in 50 mM Hepes (pH 7.5). Complexes of
chimera 264 decorated with PA83 were pelleted by centrifugation at
197,568g at 11 8C in an SW41Ti rotor for 1.5 h or an SW 55 Ti rotor
for 45 min. The complexes were resuspended in 50 mM Hepes and
analyzed by electrophoresis to conﬁrm the presence of chimera 264
and PA83 proteins.
Rat immunization and LeTx challenge. Immunization studies were
performed in male Harlan Sprague Dawley rats (180–200g, Harlan)
according to protocols approved by the Scripps Institutional Animal
Care and Use Committee. For double dose immunization, rats were
injected subcutaneously with 200 ll containing either 2.5 lgo fP A 83
(List Biological Laboratories), 5.4 lg of FHV- VWAANTXR2-264-PA83
(molar equivalent of 2.5 lgP A 83), or 2.9 lg FHV-VWAANTXR2-264
(molar equivalent of particles complexed with PA83) all prepared in
PBS. For single dose immunization, rats were injected subcutaneously
with 200 ll containing either 5 lgo fP A 83, 10.8 lg of FHV-
VWAANTXR2-264-PA83 (molar equivalent of 5 lgP A 83), or 5.8 lgo f
FHV-VWAANTXR2-264 (molar equivalent of particles complexed with
PA83) all in PBS. Rats were anesthetized with isoﬂuorane before all
procedures. Serum was prepared from blood (200 ll per rat) collected
from the retro-orbital plexus before immunization, 3 wk post
primary immunization, and 4 wk post secondary immunization
(study 1 only). LeTx challenge experiments were performed 13 wk
post initial immunization for the double dose immunization study
and 4 wk post immunization for the single dose immunization study.
LeTx for each rat was prepared by mixing 40 lg of PA and 8 lgo fL F
(List Biological Laboratories) in PBS. Rats were anesthetized with
isoﬂuorane and inoculated with 500 ll of LeTx or PBS (control) by
intravenous tail vein injection. Rats recovered from anesthesia within
5 min after dosing and were monitored for symptoms of intoxication
and death as described above.
Antibody detection. Serum samples were tested for antibody
response to PA, ANTXR2, and FHV by ELISA assays. Brieﬂy,
microtitre Immulon 2HB 96-well plates (Dynex Technologies) were
coated with 100 llo f1 0lg/ml PA83, sANTXR2, or FHV in coating
buffer (0.1 M NaHCO3 [pH 8.5]), blocked with 3% non-fat milk in
TBS, and incubated with serum samples diluted 1:100 and 1:1,000 in
1% non-fat milk in TBS (pH 7.0) with 0.05% Tween 20 for 1 h at
room temperature. After washing, wells were incubated with biotin-
SP-conjugated donkey anti-rat IgG (Jackson ImmunoResearch)
diluted 1:20,000 for 1 h at room temperature. Plates were washed
and incubated for 45 min with streptavidin-alkaline phosphatase
conjugate (GE Healthcare Bio-Sciences) diluted 1:5,000 in TBS. After
washing, plates were incubated with p-nitriphenyl phosphate (Sigma-
Aldrich) at 37 8C for 20 min. 2 N NaOH was added to stop the
reaction and the signal was quantiﬁed using an ELISA reader
(Molecular Devices) at 405 nm.
Supporting Information
Figure S1. 3-D Surface-Shaded Reconstructions of (A) FHV-
VWAANTXR2 Chimera 206, (B) FHV-VWAANTXR2 Chimera 264, and
(C) wt FHV
Note the protruding surface densities on the chimeric VLPs due to
the addition of the VWA domain of ANTXR2. Bar ¼ 100 A ˚ .
Found at doi:10.1371/journal.ppat.0030142.sg001 (304 KB TIF).
Figure S2. Pseudoatomic Models of FHV-VWAANTXR2 Chimeras
X-ray coordinates of FHV capsid protein (green) and ANTXR2 VWA
domain (yellow) were docked into the cryoEM density (grey) of
chimera 206 (A) and chimera 264 (B). Shown are octants of the
density maps to illustrate the good ﬁt of the high resolution X-ray
structures into the cryoEM maps. Density within the interior of the
capsid shell is ascribed to the encapsidated RNA.
Found at doi:10.1371/journal.ppat.0030142.sg002 (794 KB TIF).
Figure S3. In Silico Model of PA83 Bound to the Surface of FHV-
VWAANTXR2 Chimeras
A maximum number of PA83 molecules (purple) was modeled onto
the surface of chimera 206 (A) and chimera 264 (B), as limited by
steric hindrance. Modeling was based on the known X-ray crystal
structures of FHV [17] and ANTXR2-VWA/PA63 complex [9]. The
FHV capsid protein and the VWA domain of ANTXR2 are in green
and yellow, respectively. Panels show cross-sections of the chimeric
particles, including the cryoEM density map (grey).
Found at doi:10.1371/journal.ppat.0030142.sg003 (959 KB TIF).
Figure S4. Quantiﬁcation of PA83 Bound to Chimera 206 and
Chimera 264
(A) Recombinant PA83 was mixed with puriﬁed chimeras 206 and 264
in a ratio of 180:1 (equimolar amounts of PA83 and VWA) and an
aliquot from each sample was removed and stored. The remainder of
the sample was centrifuged through a sucrose cushion to remove
unbound PA83 and the pellet was resuspended in electrophoresis
buffer. Aliquots were electrophoresed through a 4%–12% Bis-Tris
polyacrylamide gel in parallel with aliquots taken before pelleting.
The gels were stained with Simply Blue (Invitrogen). Lane 1,
molecular weight markers; lane 2, PA83 and chimera 206 before
pelleting; lane 3, PA83 and chimera 206 after pelleting; lane 4, PA83
and chimera 264 before pelleting; lane 5, PA83 and chimera 264 after
pelleting. (B) Quantitative representation of PA83 associated with
chimeric particles after pelleting. Protein representing PA83 and
chimeras 206 and 264 shown in (A) was quantiﬁed by densitometric
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FHV-Based Anthrax Antitoxin and Vaccineanalysis using FluorChem SP (Alpha Innotech) and the number of PA
molecules bound to the particles calculated. The numbers were
normalized to the amount of protein in the respective samples before
pelleting.
Found at doi:10.1371/journal.ppat.0030142.sg004 (963 KB TIF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
bers for the proteins discussed in this paper are Flock House virus
coat protein (NC004144) and human capillary morphogenesis protein
2 (CMG2) (AY23345).
Protein Data Bank (http://www.rcsb.org/pdb/) accession numbers
are for the VWA domain of CMG2 (1SHT) and B. anthracis protective
antigen PA63 complexed with CMG2 (1T6B).
The Virus Particle Explorer (http://viperdb.scripps.edu/) was used
for Flock House virus particle coordinates.
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Note Added in Proof
References [9] and [10] are cited out of order and appear later in the article
than where numerical order would put them.
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